https://www.selleckchem.com/products/AZD0530.html
001) compared to the PDH-E1α-negative group. Patients with NSCLC showing PDH-E1α-negative expression had a significantly poorer overall survival rate (P=0.007) than those showing PDH-E1α-positive expression, especially at stage II. Patients with PDH-E1α negative expression also showed a poorer disease-free survival rate (P=0.02). Multivariate analysis revealed that PDH-E1α negativity (P=0.037) and male sex (P0.001) were significantly correlated with a poor overall survival. PDH-E1α may represent a reliable prognostic predictor for N
Like
Comment
Share
